| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thromboxane B2 | 9 | 2026 | 19 | 3.120 |
Why?
|
| Aspirin | 10 | 2025 | 172 | 2.940 |
Why?
|
| Platelet Aggregation Inhibitors | 14 | 2021 | 235 | 2.610 |
Why?
|
| Coronary Artery Bypass | 7 | 2017 | 292 | 1.830 |
Why?
|
| Blood Platelets | 8 | 2025 | 108 | 1.750 |
Why?
|
| Graft Occlusion, Vascular | 6 | 2016 | 60 | 1.600 |
Why?
|
| Saphenous Vein | 5 | 2016 | 51 | 1.490 |
Why?
|
| Thrombomodulin | 8 | 2011 | 17 | 1.480 |
Why?
|
| Acute Coronary Syndrome | 6 | 2021 | 254 | 1.330 |
Why?
|
| Thromboxanes | 5 | 2024 | 10 | 1.310 |
Why?
|
| Myocardial Infarction | 11 | 2020 | 922 | 1.250 |
Why?
|
| Percutaneous Coronary Intervention | 9 | 2021 | 226 | 1.180 |
Why?
|
| Thromboxane A2 | 3 | 2026 | 6 | 1.170 |
Why?
|
| Thrombosis | 7 | 2025 | 207 | 1.100 |
Why?
|
| Coronary Artery Disease | 6 | 2021 | 326 | 1.060 |
Why?
|
| Heart Failure | 5 | 2026 | 968 | 0.990 |
Why?
|
| Cardiovascular Diseases | 4 | 2026 | 878 | 0.940 |
Why?
|
| Cardiac Catheterization | 5 | 2021 | 293 | 0.840 |
Why?
|
| Venous Thrombosis | 4 | 2011 | 113 | 0.830 |
Why?
|
| Ticlopidine | 3 | 2013 | 47 | 0.780 |
Why?
|
| Endothelial Cells | 3 | 2011 | 216 | 0.750 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2020 | 171 | 0.720 |
Why?
|
| Biomarkers | 9 | 2026 | 1503 | 0.710 |
Why?
|
| Endothelium, Vascular | 6 | 2009 | 180 | 0.710 |
Why?
|
| Platelet Activation | 5 | 2019 | 31 | 0.640 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2011 | 29 | 0.630 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 284 | 0.630 |
Why?
|
| Myocardial Revascularization | 1 | 2020 | 78 | 0.630 |
Why?
|
| Jugular Veins | 4 | 2011 | 28 | 0.620 |
Why?
|
| Coronary Disease | 3 | 2014 | 247 | 0.600 |
Why?
|
| Myocardial Ischemia | 2 | 2012 | 121 | 0.600 |
Why?
|
| Risk Factors | 12 | 2026 | 5475 | 0.600 |
Why?
|
| Male | 41 | 2026 | 31410 | 0.600 |
Why?
|
| Middle Aged | 27 | 2026 | 18501 | 0.590 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2021 | 15 | 0.590 |
Why?
|
| Humans | 56 | 2026 | 65845 | 0.570 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2021 | 96 | 0.570 |
Why?
|
| Electrocardiography | 2 | 2020 | 556 | 0.570 |
Why?
|
| Aged | 24 | 2026 | 15147 | 0.570 |
Why?
|
| Time Factors | 14 | 2020 | 3779 | 0.550 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2015 | 20 | 0.530 |
Why?
|
| Platelet Factor 4 | 2 | 2009 | 12 | 0.520 |
Why?
|
| NF-kappa B | 3 | 2009 | 436 | 0.520 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2018 | 46 | 0.500 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2013 | 7 | 0.490 |
Why?
|
| Heparin | 2 | 2009 | 120 | 0.480 |
Why?
|
| Creatinine | 3 | 2024 | 136 | 0.470 |
Why?
|
| Female | 31 | 2026 | 34425 | 0.450 |
Why?
|
| Treatment Outcome | 15 | 2020 | 5834 | 0.440 |
Why?
|
| Stress, Mechanical | 3 | 2011 | 119 | 0.420 |
Why?
|
| Cells, Cultured | 11 | 2021 | 2194 | 0.410 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 6 | 0.400 |
Why?
|
| Pyridines | 1 | 2014 | 120 | 0.400 |
Why?
|
| Hematocrit | 1 | 2013 | 32 | 0.400 |
Why?
|
| Risk Assessment | 7 | 2026 | 2116 | 0.370 |
Why?
|
| Adenoviridae | 9 | 2008 | 132 | 0.370 |
Why?
|
| Blood Pressure | 2 | 2006 | 537 | 0.360 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 28 | 0.360 |
Why?
|
| Stroke Volume | 3 | 2025 | 346 | 0.360 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2011 | 7 | 0.340 |
Why?
|
| Quinazolines | 1 | 2011 | 21 | 0.340 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 61 | 0.340 |
Why?
|
| Thiophenes | 1 | 2011 | 31 | 0.340 |
Why?
|
| Genetic Therapy | 5 | 2008 | 852 | 0.330 |
Why?
|
| Piperazines | 1 | 2011 | 86 | 0.330 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2010 | 23 | 0.330 |
Why?
|
| Myocardium | 3 | 2020 | 302 | 0.320 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 68 | 0.320 |
Why?
|
| Drug Resistance | 1 | 2011 | 158 | 0.310 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2021 | 9 | 0.310 |
Why?
|
| Receptor, PAR-1 | 2 | 2020 | 5 | 0.300 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 62 | 0.300 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 220 | 0.300 |
Why?
|
| Proteasome Inhibitors | 1 | 2009 | 32 | 0.300 |
Why?
|
| Boronic Acids | 1 | 2009 | 28 | 0.300 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2009 | 48 | 0.300 |
Why?
|
| Pyrazines | 1 | 2009 | 35 | 0.300 |
Why?
|
| Gene Expression Regulation | 4 | 2005 | 1635 | 0.290 |
Why?
|
| Fibroblast Growth Factor 4 | 2 | 2008 | 7 | 0.290 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 129 | 0.290 |
Why?
|
| Platelet Aggregation | 4 | 2013 | 24 | 0.280 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 109 | 0.280 |
Why?
|
| Prasugrel Hydrochloride | 3 | 2021 | 13 | 0.280 |
Why?
|
| Prognosis | 3 | 2024 | 1793 | 0.270 |
Why?
|
| Hirudins | 3 | 1999 | 12 | 0.270 |
Why?
|
| Angina Pectoris | 2 | 2005 | 35 | 0.270 |
Why?
|
| Neovascularization, Physiologic | 2 | 2008 | 113 | 0.270 |
Why?
|
| Atherosclerosis | 2 | 2021 | 162 | 0.270 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 145 | 0.250 |
Why?
|
| Endocardium | 1 | 2006 | 14 | 0.250 |
Why?
|
| Genetic Vectors | 10 | 2008 | 930 | 0.240 |
Why?
|
| Stents | 2 | 2020 | 500 | 0.240 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1117 | 0.240 |
Why?
|
| Lipopeptides | 3 | 2021 | 15 | 0.240 |
Why?
|
| Heart Rate | 3 | 2006 | 335 | 0.240 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2500 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 645 | 0.230 |
Why?
|
| Cell-Penetrating Peptides | 3 | 2021 | 29 | 0.230 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2025 | 36 | 0.220 |
Why?
|
| United States | 8 | 2021 | 8189 | 0.220 |
Why?
|
| Leukocytes | 1 | 2025 | 110 | 0.220 |
Why?
|
| Antibody Formation | 1 | 2005 | 111 | 0.220 |
Why?
|
| Rabbits | 4 | 2011 | 342 | 0.220 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 932 | 0.210 |
Why?
|
| Interleukin-1 | 1 | 2005 | 154 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 605 | 0.210 |
Why?
|
| Protein C | 3 | 2011 | 26 | 0.210 |
Why?
|
| Coronary Circulation | 3 | 2011 | 55 | 0.200 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 180 | 0.200 |
Why?
|
| Vascular Patency | 2 | 2016 | 135 | 0.200 |
Why?
|
| Carotid Arteries | 4 | 2011 | 64 | 0.200 |
Why?
|
| Angina, Unstable | 1 | 2003 | 56 | 0.190 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 387 | 0.190 |
Why?
|
| Animals | 18 | 2021 | 21493 | 0.190 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 80 | 0.190 |
Why?
|
| Feedback, Physiological | 1 | 2003 | 59 | 0.190 |
Why?
|
| Estrogens | 1 | 2003 | 115 | 0.180 |
Why?
|
| Progesterone | 1 | 2003 | 165 | 0.180 |
Why?
|
| Antithrombins | 2 | 1999 | 16 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2021 | 3340 | 0.180 |
Why?
|
| Retroviridae | 2 | 1999 | 75 | 0.180 |
Why?
|
| Registries | 3 | 2021 | 935 | 0.180 |
Why?
|
| Blood Coagulation Factors | 1 | 2002 | 16 | 0.180 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2011 | 53 | 0.180 |
Why?
|
| Adenosine Diphosphate | 2 | 2013 | 44 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2005 | 344 | 0.170 |
Why?
|
| Kidney | 1 | 2024 | 460 | 0.170 |
Why?
|
| Fibrillar Collagens | 1 | 2021 | 1 | 0.170 |
Why?
|
| Pandemics | 3 | 2020 | 691 | 0.170 |
Why?
|
| Troponin | 1 | 2020 | 39 | 0.160 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 125 | 0.160 |
Why?
|
| Gene Transfer Techniques | 5 | 2008 | 325 | 0.160 |
Why?
|
| Adult | 10 | 2026 | 17579 | 0.160 |
Why?
|
| Aorta | 1 | 2021 | 108 | 0.160 |
Why?
|
| Coronary Angiography | 2 | 2011 | 212 | 0.160 |
Why?
|
| Collagen | 2 | 2011 | 135 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 432 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 462 | 0.140 |
Why?
|
| Monocytes | 1 | 2021 | 362 | 0.140 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2020 | 62 | 0.140 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2018 | 8 | 0.140 |
Why?
|
| Influenza A virus | 1 | 2019 | 122 | 0.130 |
Why?
|
| Gene Expression | 4 | 1999 | 856 | 0.130 |
Why?
|
| Urinalysis | 1 | 2017 | 37 | 0.130 |
Why?
|
| Carotid Artery Diseases | 1 | 2018 | 61 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2018 | 65 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2329 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 221 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2013 | 29 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 420 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2019 | 213 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2016 | 323 | 0.120 |
Why?
|
| Recurrence | 3 | 2021 | 665 | 0.120 |
Why?
|
| Rats | 5 | 2006 | 2005 | 0.120 |
Why?
|
| Prevalence | 1 | 2020 | 1454 | 0.120 |
Why?
|
| Dinoprost | 1 | 2016 | 18 | 0.120 |
Why?
|
| Carotid Artery Injuries | 1 | 1996 | 14 | 0.120 |
Why?
|
| Apoptosis | 1 | 2021 | 1100 | 0.120 |
Why?
|
| Atrioventricular Node | 3 | 2006 | 9 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 746 | 0.110 |
Why?
|
| Hospitalization | 2 | 2021 | 1404 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 140 | 0.110 |
Why?
|
| Coronary Stenosis | 1 | 2015 | 41 | 0.110 |
Why?
|
| Cardiac Care Facilities | 1 | 2014 | 2 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 712 | 0.100 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 1663 | 0.100 |
Why?
|
| Professional Competence | 1 | 2014 | 91 | 0.100 |
Why?
|
| Radial Artery | 1 | 2014 | 55 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6957 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2004 | 15 | 0.100 |
Why?
|
| Troponin I | 2 | 2010 | 36 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2012 | 103 | 0.090 |
Why?
|
| Cross Reactions | 1 | 2012 | 140 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 119 | 0.090 |
Why?
|
| Stroke | 2 | 2021 | 1225 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5682 | 0.090 |
Why?
|
| Fibrinolytic Agents | 3 | 2018 | 183 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 143 | 0.090 |
Why?
|
| Aldehyde Reductase | 1 | 2011 | 3 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 449 | 0.090 |
Why?
|
| Paracrine Communication | 1 | 2011 | 17 | 0.090 |
Why?
|
| Contraindications | 1 | 2011 | 52 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 12 | 0.090 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 117 | 0.090 |
Why?
|
| Molecular Sequence Data | 4 | 2013 | 1980 | 0.090 |
Why?
|
| Platelet Count | 1 | 2011 | 27 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2011 | 66 | 0.080 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2010 | 9 | 0.080 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 413 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2011 | 208 | 0.080 |
Why?
|
| Myoglobin | 1 | 2010 | 29 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 518 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 223 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2021 | 611 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2003 | 165 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2011 | 89 | 0.080 |
Why?
|
| Mice, Knockout, ApoE | 2 | 2021 | 2 | 0.080 |
Why?
|
| Shear Strength | 1 | 2009 | 20 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2011 | 757 | 0.080 |
Why?
|
| Health Personnel | 1 | 2014 | 391 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1172 | 0.080 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2021 | 34 | 0.080 |
Why?
|
| Mice, Inbred C3H | 1 | 2009 | 173 | 0.070 |
Why?
|
| Bortezomib | 1 | 2009 | 60 | 0.070 |
Why?
|
| Epinephrine | 1 | 2009 | 46 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 171 | 0.070 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2000 | 126 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2011 | 502 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 995 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 59 | 0.070 |
Why?
|
| Base Sequence | 3 | 2003 | 1332 | 0.070 |
Why?
|
| Collateral Circulation | 1 | 2008 | 28 | 0.070 |
Why?
|
| Logistic Models | 1 | 2011 | 1274 | 0.070 |
Why?
|
| Survival Rate | 2 | 2014 | 849 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 875 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 811 | 0.070 |
Why?
|
| Serotonin | 2 | 2005 | 62 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 3506 | 0.070 |
Why?
|
| Mice | 3 | 2021 | 11185 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 272 | 0.060 |
Why?
|
| Massachusetts | 2 | 2026 | 2158 | 0.060 |
Why?
|
| Bundle of His | 1 | 2006 | 3 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 88 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2006 | 15 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2006 | 184 | 0.060 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2026 | 7 | 0.060 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2026 | 18 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2026 | 38 | 0.060 |
Why?
|
| Vascular Stiffness | 1 | 2026 | 17 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 1590 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 1229 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2011 | 1583 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2026 | 41 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 484 | 0.060 |
Why?
|
| Adiposity | 1 | 2026 | 89 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2026 | 147 | 0.060 |
Why?
|
| Immune Complex Diseases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Myocardial Stunning | 1 | 2005 | 6 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2005 | 19 | 0.060 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2005 | 9 | 0.060 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2005 | 14 | 0.050 |
Why?
|
| Catecholamines | 1 | 2005 | 31 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2008 | 745 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2005 | 81 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 6 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 23 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2003 | 15 | 0.050 |
Why?
|
| E-Selectin | 1 | 2003 | 19 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 54 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 77 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 491 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 365 | 0.050 |
Why?
|
| Vinblastine | 1 | 2003 | 15 | 0.050 |
Why?
|
| Leukopenia | 1 | 2003 | 16 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2005 | 321 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2009 | 2651 | 0.050 |
Why?
|
| Granulocytes | 1 | 2003 | 73 | 0.050 |
Why?
|
| Vasculitis | 1 | 2003 | 49 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2020 | 747 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 417 | 0.040 |
Why?
|
| Tunica Intima | 1 | 2002 | 16 | 0.040 |
Why?
|
| Thrombin | 1 | 2002 | 23 | 0.040 |
Why?
|
| Adenoviridae Infections | 2 | 2003 | 5 | 0.040 |
Why?
|
| Models, Animal | 1 | 2003 | 243 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 690 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 462 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2002 | 128 | 0.040 |
Why?
|
| Postmenopause | 1 | 2003 | 241 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 542 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2031 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 253 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 39 | 0.040 |
Why?
|
| North America | 1 | 2021 | 114 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 139 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 157 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2003 | 332 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 39 | 0.040 |
Why?
|
| Transfection | 2 | 1999 | 700 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2005 | 475 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 172 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 793 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 242 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2018 | 3170 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 147 | 0.040 |
Why?
|
| Hirudin Therapy | 1 | 1999 | 2 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1999 | 19 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 1999 | 25 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 193 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 307 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 899 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 36 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2002 | 240 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 162 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 451 | 0.040 |
Why?
|
| Growth Hormone | 1 | 1999 | 18 | 0.040 |
Why?
|
| Complement C3 | 1 | 2019 | 61 | 0.040 |
Why?
|
| Protein Sorting Signals | 1 | 1999 | 55 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 279 | 0.040 |
Why?
|
| Extracellular Traps | 1 | 2019 | 45 | 0.040 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2019 | 104 | 0.030 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2018 | 7 | 0.030 |
Why?
|
| Atrial Fibrillation | 2 | 2004 | 884 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 27 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 29 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1999 | 215 | 0.030 |
Why?
|
| Hospitals | 1 | 2021 | 399 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2019 | 204 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1997 | 626 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 165 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 162 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2018 | 135 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 1999 | 296 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1997 | 10 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 1997 | 30 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1122 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 1561 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 710 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 881 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 667 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 396 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 51 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 413 | 0.030 |
Why?
|
| Learning Curve | 1 | 2014 | 33 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2168 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1993 | 84 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2013 | 96 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 2 | 2004 | 5 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2014 | 105 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 120 | 0.020 |
Why?
|
| Models, Biological | 2 | 2011 | 1193 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 238 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2013 | 261 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 153 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2013 | 224 | 0.020 |
Why?
|
| Phospholipase C gamma | 1 | 2011 | 11 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 672 | 0.020 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2011 | 5 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 12 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2011 | 102 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2011 | 55 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4883 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 922 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 238 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6368 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 372 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 1161 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 464 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1148 | 0.020 |
Why?
|
| Arabinose | 1 | 1987 | 4 | 0.020 |
Why?
|
| Operon | 1 | 1987 | 31 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 558 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2005 | 42 | 0.010 |
Why?
|
| Diltiazem | 1 | 2004 | 2 | 0.010 |
Why?
|
| Propanolamines | 1 | 2004 | 10 | 0.010 |
Why?
|
| Digoxin | 1 | 2004 | 23 | 0.010 |
Why?
|
| Sus scrofa | 1 | 2004 | 30 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2004 | 35 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 296 | 0.010 |
Why?
|
| Chest Pain | 1 | 2005 | 86 | 0.010 |
Why?
|
| Hydrazines | 1 | 2003 | 9 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2003 | 18 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2003 | 21 | 0.010 |
Why?
|
| Nitrogen Oxides | 1 | 2003 | 11 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 579 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 102 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 34 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 859 | 0.010 |
Why?
|
| Adenosine | 1 | 2003 | 79 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 96 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 665 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 196 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 503 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2003 | 165 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 491 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 541 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 993 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 206 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2003 | 273 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 419 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2000 | 31 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 2000 | 52 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2000 | 89 | 0.010 |
Why?
|
| Papio | 1 | 1999 | 22 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 320 | 0.010 |
Why?
|
| Swine | 1 | 2000 | 398 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 1336 | 0.010 |
Why?
|
| Arteritis | 1 | 1997 | 4 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1997 | 126 | 0.010 |
Why?
|
| Immunization | 1 | 1997 | 135 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 153 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1997 | 329 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1999 | 1391 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1993 | 58 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 1987 | 73 | 0.000 |
Why?
|
| Genes, Bacterial | 1 | 1987 | 115 | 0.000 |
Why?
|
| Plasmids | 1 | 1987 | 294 | 0.000 |
Why?
|
| Amino Acids | 1 | 1987 | 148 | 0.000 |
Why?
|
| DNA, Bacterial | 1 | 1987 | 262 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1987 | 333 | 0.000 |
Why?
|
| Escherichia coli Proteins | 1 | 1987 | 278 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1987 | 719 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1987 | 718 | 0.000 |
Why?
|